Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/67320

TitleLow fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question
Author(s)Monteiro, Sara
Dias de Castro, Francisca
Leite, Sílvia
Moreira, Maria João
Cotter, José Almeida Berkeley
KeywordsAdult
Area Under Curve
Biomarkers
Crohn Disease
Feces
Female
Humans
Kaplan-Meier Estimate
Leukocyte L1 Antigen Complex
Male
Middle Aged
ROC Curve
Recurrence
Remission Induction
Retrospective Studies
Severity of Illness Index
Inflammatory bowel diseases
Prognosis
Crohn's disease
Issue dateJan-2019
PublisherTaylor and Francis
JournalScandinavian Journal of Gastroenterology
CitationMonteiro, S., Dias de Castro, F., Leite, S., et. al. (2019). Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. Scandinavian journal of gastroenterology, 54(1), 49-54
Abstract(s)Fecal calprotectin (FC) is a noninvasive marker of intestinal inflammation. Predicting relapses in Crohn's disease (CD) patients can allow earlier changes in therapy. The aim of this study was to evaluate the role of FC in predicting relapse in CD patients in clinical remission within six months follow-up. Background and aim: Fecal calprotectin (FC) is a noninvasive marker of intestinal inflammation. Predicting relapses in Crohn’s disease (CD) patients can allow earlier changes in therapy. The aim of this study was to evaluate the role of FC in predicting relapse in CD patients in clinical remission within six months follow-up. Methods: Patients with CD who were in clinical remission at least ≥3 months were included in this study. The first FC sample during the remission period was evaluated and was used as the baseline value. Relapse was defined as an unexpected escalation in therapy, hospitalization or need for surgery for active CD. The accuracy and optimal cutoff FC values for predicting clinical relapse at six months were assessed by the area under the ROC curve (AUC). Results: One hundred and forty-four patients were evaluated, with mean age of 38.4 years. Of these, 13 (9%) had a relapse during the follow-up period. The mean FC value was significantly lower for non-relapsers (203.2 μg/g) than for relapsers (871.3 μg/g), p < .001. The AUC for predicting relapse by using FC values was 0.924. The optimal cutoff FC value to predict relapse was 327 μg/g; with values of sensitivity, specificity, negative predictive value and positive predictive value were 92.3%, 82.4%, 99.1% and 34.3%, respectively. Conclusions: FC is more useful in predicting remission maintenance than relapse in patients with CD in clinical remission. Values of FC ≤327 μg/g can exclude relapse at least at six months follow-up period.
TypeArticle
URIhttp://hdl.handle.net/1822/67320
DOI10.1080/00365521.2018.1549683
ISSN0036-5521
e-ISSN1502-7708
Publisher versionhttps://www.tandfonline.com/doi/abs/10.1080/00365521.2018.1549683
Peer-Reviewedyes
AccessRestricted access (Author)
Appears in Collections:ICVS - Artigos em revistas internacionais / Papers in international journals

Files in This Item:
File Description SizeFormat 
monteiro2019.pdf
  Restricted access
813,08 kBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID